3-chloro-2-hydroxy-benzoic acid ethyl ester | 56961-32-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-chloro-2-hydroxy-benzoic acid ethyl ester
• 英文别名: 3-Chlor-2-hydroxy-benzoesaeure-aethylester；Ethyl 3-chloro-2-hydroxybenzoate
• CAS: 56961-32-1
• 化学式: C₉H₉ClO₃
• 分子量: 200.622
• InChiKey: ODGDGWPLWHOHEP-UHFFFAOYSA-N

物化性质

• 熔点：
  21°C
• 沸点：
  288.02°C (rough estimate)
• 密度：
  1.2799 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  3-氯水杨酸	3-Chloro-2-hydroxybenzoic acid	1829-32-9	C7H5ClO3	172.568
  水杨酸乙酯	2-hydroxy-benzoic acid ethyl ester	118-61-6	C9H10O3	166.177

反应信息

• 作为反应物：
  描述：

  ethyl (3S,4aR,6R,8aR)-6-hydroxy-2-(tert-butoxycarbonyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylate 、 3-chloro-2-hydroxy-benzoic acid ethyl ester 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 生成
  参考文献：
  名称：

  GluK1 antagonists from 6-(carboxy)phenyl decahydroisoquinoline derivatives. SAR and evaluation of a prodrug strategy for oral efficacy in pain models

  摘要：

  The synthesis and structure-activity relationship of decahydroisoquinoline derivatives with various benzoic acid substitutions as GluK1 antagonists are described. Potent and selective antagonists were selected for a tailored prodrug approach in order to facilitate the evaluation of the new compounds in pain models after oral administration. Several diester prodrugs allowed for acceptable amino acid exposure and moderate efficacy in vivo. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.09.046
• 作为产物：
  描述：

  水杨酸乙酯 以22%的产率得到
  参考文献：
  名称：

  CHUNG, KUN NOE;KIM, HAK JIN;KIM, HYOUNG RAE;RYU, EUNG K., SYNTH. COMMUN., 20,(1990) N9, C. 2991-2997

  摘要：

  DOI：

文献信息

• Synthesis, antibacterial activity, and quantitative structure–activity relationships of new (Z)-2-(nitroimidazolylmethylene)-3()-benzofuranone derivatives
  作者：Narges Hadj-esfandiari、Latifeh Navidpour、Hooman Shadnia、Mohsen Amini、Nasrin Samadi、Mohammad Ali Faramarzi、Abbas Shafiee

  DOI：10.1016/j.bmcl.2007.09.062

  日期：2007.11

  A new series of (Z)-2-(1-methyl-5-nitroimidazole-2-ylmethylene)-3(2H)-benzofuranones (11a-p) and (Z)-2-(1-methyl-4-nitroimidazole-5-ylmethylene)-3(2H)-benzofuranones (12a-m) were synthesized and assayed for their antibacterial activity against Gram-positive and Gram-negative bacteria. Most of the 5-nitroimidazole analogues (11a-p) showed a remarkable inhibition of a wide spectrum of Gram-positive bacteria (Staphylococcus aureus, Streptococcus epidermidis, MRSA, and Bacillus subtilis) and Gram-negative Klebsiella pneumoniae, whereas 4-nitroimidazole analogues (12a-m) were not effective against selected bacteria. The quantitative structure-activity relationship investigations were applied to find out the correlation between the experimentally evaluated activities with various parameters of the compounds studied. The QSAR models built in this work had reasonable predictive power and could be explained by the observed trends in activities. (C) 2007 Elsevier Ltd. All rights reserved.
• Anschuetz,R.; Anspach, Justus Liebigs Annalen der Chemie, 1906, vol. 346, p. 312
  作者：Anschuetz,R.、Anspach

  DOI：——

  日期：——
• CHUNG, KUN NOE;KIM, HAK JIN;KIM, HYOUNG RAE;RYU, EUNG K., SYNTH. COMMUN., 20,(1990) N9, C. 2991-2997
  作者：CHUNG, KUN NOE、KIM, HAK JIN、KIM, HYOUNG RAE、RYU, EUNG K.

  DOI：——

  日期：——
• GluK1 antagonists from 6-(carboxy)phenyl decahydroisoquinoline derivatives. SAR and evaluation of a prodrug strategy for oral efficacy in pain models
  作者：Jose A. Martinez-Perez、Smriti Iyengar、Harlan E. Shannon、David Bleakman、Andrew Alt、Brian M. Arnold、Michael G. Bell、Thomas J. Bleisch、Ana M. Castaño、Miriam Del Prado、Esteban Dominguez、Ana M. Escribano、Sandra A. Filla、Ken H. Ho、Kevin J. Hudziak、Carrie K. Jones、Ana Mateo、Brian M. Mathes、Edward L. Mattiuz、Ann Marie L. Ogden、Rosa Maria A. Simmons、Douglas R. Stack、Robert E. Stratford、Mark A. Winter、Zhipei Wu、Paul L. Ornstein

  DOI：10.1016/j.bmcl.2013.09.046

  日期：2013.12

  The synthesis and structure-activity relationship of decahydroisoquinoline derivatives with various benzoic acid substitutions as GluK1 antagonists are described. Potent and selective antagonists were selected for a tailored prodrug approach in order to facilitate the evaluation of the new compounds in pain models after oral administration. Several diester prodrugs allowed for acceptable amino acid exposure and moderate efficacy in vivo. (C) 2013 Elsevier Ltd. All rights reserved.